This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cutera CEO Discusses Q4 2010 Results - Earnings Call Transcript

Additionally, we recognized record revenue in Japan in the fourth quarter of 2010. Our Japanese operations experienced growth in all the product categories, including the recently added filler in the cosmeceutical business. during the fourth quarter 2010, approximately 67% of our North American orders came from the core market of podiatrists. The podiatry specialty is a new perfect market for us, an opportunity to sell our Genesis Plus and other products. We are continuing to target the core market segments, as well as other established medical offices because we believe they offer the best growth opportunities in the current market environment.

Titan annuity revenue for the fourth quarter 2010 was in line with our expectations at $934,000, a decrease of $590,000 from the same quarter in the prior year. This decrease was primarily due to the voluntary recall of certain Titan XL hand pieces. We provided our eligible customers with a fully refilled Titan XL hand pieces, which resulted in lower than normal Titan refill revenue. We are pleased with the sequential increase of approximately $300,000 of annuity revenue from the third quarter, which we believe will continue to increase until the return to a normalized quarterly revenue of $1.5 million in the second half of 2011.

Turning to the cosmeceutical and filler products, in the fourth quarter of 2010 we had record revenue of $1.2 million from these products. as a reminder, in Japan we started distributing Obagi physician dispensed cosmeceutical products from February 2010, and has been distributing BioForm's Radiesse products since late 2008. These products augment our Cutera laser and light-based products. We are pleased with the recurrent revenue model and profit contributions, as well as the cross selling opportunities that these products provide. Currently, the cosmeceutical filler business and Cutera laser and light-based installed base overlaps by approximately only 10%.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs